LON:ETX - e-Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 2.08 0.00 (0.00 %) (As of 05/20/2019 04:00 PM ET)Previous CloseGBX 2.08Today's RangeGBX 2.16 - GBX 2.1652-Week RangeGBX 2.10 - GBX 8.65Volume6,248 shsAverage Volume54,267 shsMarket Capitalization£5.59 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartEarningsInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email e-Therapeutics plc engages in the discovery of drugs through its proprietary network-driven drug discovery platform in the United Kingdom. It is developing two NDD-derived immuno-oncology programs, including tryptophan catabolism and immune checkpoint modulation. The company, through its subsidiary, Searchbolt Limited, develops search engine technology. The company has collaborations with C4X Holdings PLC, Intellegens, Biorelate, and Novo Nordisk. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom. Receive ETX News and Ratings via Email Sign-up to receive the latest news and ratings for ETX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:ETX Previous Symbol CUSIPN/A CIKN/A Webwww.etherapeutics.co.uk Phone+44-1993-880000Debt Debt-to-Equity RatioN/A Current Ratio10.39 Quick Ratio9.93Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£44,000.00 Price / Sales127.02 Cash FlowGBX 2.18 per share Price / Cash Flow0.95 Book ValueGBX 2.50 per share Price / Book0.83Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees18 Outstanding Shares268,689,984Market Cap£5.59 million Next Earnings DateN/A OptionableNot Optionable e-Therapeutics (LON:ETX) Frequently Asked Questions What is e-Therapeutics' stock symbol? e-Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ETX." How were e-Therapeutics' earnings last quarter? e-Therapeutics plc (LON:ETX) released its earnings results on Tuesday, March, 27th. The company reported ($2.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.10) by $0.10. View e-Therapeutics' Earnings History. Has e-Therapeutics been receiving favorable news coverage? Media stories about ETX stock have trended somewhat negative recently, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. e-Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of e-Therapeutics' key competitors? Some companies that are related to e-Therapeutics include Altimmune (ALT), Quest PharmaTech (QPT), Adalta (1AD), Oragenics (OGEN), biOasis Technologies (BTI), Rexahn Pharmaceuticals (RNN), Rexahn Pharmaceuticals (RNN), Anatara Lifesciences (ANR), Medicenna Therapeutics (MDNA), Galena Biopharma (SLS), Hvivo (HVO), Devonian Health Group (GSD), Scancell (SCLP), Actinogen Medical (ACW) and Living Cell Technologies (LCT). What other stocks do shareholders of e-Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other e-Therapeutics investors own include Radware (RDWR), Inflarx (IFRX), iShares Nasdaq Biotechnology ETF (IBB), US Ecology (ECOL), Dollar Tree (DLTR), Chicken Soup for The Soul Entrtnmnt (CSSE), Bazaarvoice (BV), Starcom (STAR), Quarto Group (QRT) and IP Group (IPO). Who are e-Therapeutics' key executives? e-Therapeutics' management team includes the folowing people: Dr. Raymond Barlow, CEO & Director (Age 50)Mr. Steven Medlicott, CFO, Fin. Director & Exec. Director (Age 54)Mr. Jonny Wray, Head of Discovery InformaticsMr. Colin Stubberfield, Head of Drug DiscoveryMr. Alan Whitmore, Head of Discovery Biology How do I buy shares of e-Therapeutics? Shares of ETX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is e-Therapeutics' stock price today? One share of ETX stock can currently be purchased for approximately GBX 2.08. How big of a company is e-Therapeutics? e-Therapeutics has a market capitalization of £5.59 million and generates £44,000.00 in revenue each year. e-Therapeutics employs 18 workers across the globe. What is e-Therapeutics' official website? The official website for e-Therapeutics is http://www.etherapeutics.co.uk/. How can I contact e-Therapeutics? e-Therapeutics' mailing address is 17 Blenheim Office Park, WITNEY, OX29 8LN, United Kingdom. The company can be reached via phone at +44-1993-880000. MarketBeat Community Rating for e-Therapeutics (LON ETX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 117 (Vote Outperform)Underperform Votes: 140 (Vote Underperform)Total Votes: 257MarketBeat's community ratings are surveys of what our community members think about e-Therapeutics and other stocks. Vote "Outperform" if you believe ETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Balance Sheet Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.